Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations

Human Reproduction

Volumn 31, Issue 5, 2016, Pages 1126-1132

  Phillips, Kelly Anne ^a,b   Collins, Ian M ^a,c   Milne, Roger L ^b,d   McLachlan, Sue Anne ^a,b,e   Friedlander, Michael ^f,g   Hickey, Martha ^h   Stern, Catharyn ^h,i   Hopper, John L ^b   Fisher, Richard ^a   Kannemeyer, Gordon ⁱ   Picken, Sandra ^a   Smith, Charmaine D ^a   Kelsey, Thomas W ^j   Anderson, Richard A ^k  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d CANCER EPIDEMIOLOGY CENTRE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h ROYAL WOMEN'S HOSPITAL   (Australia)

ⁱ MELBOURNE IVF   (Australia)

^j UNIVERSITY OF ST ANDREWS   (United Kingdom)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

anti M llerian hormone; BRCA1; BRCA2; DNA repair; fertility; ovarian reserve; reproduction

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MUELLERIAN INHIBITING FACTOR; BIOLOGICAL MARKER; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FEMALE FERTILITY; GENETIC ASSOCIATION; GERMLINE MUTATION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARIAN RESERVE; RISK ASSESSMENT; AUSTRALIA; BLOOD; DNA REPAIR; GENETICS; HETEROZYGOTE; MIDDLE AGED; NEW ZEALAND;

ADULT; ANTI-MULLERIAN HORMONE; AUSTRALIA; BIOMARKERS; BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA REPAIR; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEW ZEALAND; OVARIAN RESERVE;

EID: 84966339522     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew044     Document Type: Article

References (41)

1. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
2. Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, Fehr D, Nardo L, Smitz J, Tremellen K, Denk B et al. Prospective study into the value of the automated Elecsys antimullerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril 2015;103:1074-1080 e1074.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
4. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-1466.
5. Bolcun-Filas E, Rinaldi VD, White ME, Schimenti JC. Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science 2014;343:533-536.
6. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, Laven JS, de Jong FH, Te Velde ER, Fauser BC et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-2539.
7. Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Weideman PC, Birch KE, Hopper JL, Phillips KA. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol 2013;31:3920-3925.
8. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 2015;47:1294-1303.
9. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, Klip H, van Leeuwen FE, group OM-p. A low number of retrieved oocytes at in vitro fertilization treatment is predictive of early menopause. Fertil Steril 2002;77:978-985.
10. Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, van der Schouw YT. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab 2013;98:2106-2115.
11. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
12. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-927.
13. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, Kim-Sing C, Tung N, Karlan B et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013;99:1724-1728.
14. Findlay JK, Hutt KJ, Hickey M, Anderson RA. What is the 'ovarian reserve'? Fertil Steril 2015;103:628-630.
15. Gassner D, Jung R. First fully automated immunoassay for anti-Mullerian hormone. Clin Chem Lab Med 2014;52:1143-1152.
16. Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM, Hjollund NH, Ernst E, Bonde JP, Anderson RA et al. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012;98:1602-1608 e1602.
17. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011;95:170-175.
18. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332-3340.
19. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update 2014;21:698-710.
20. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-1078.
21. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6:R375-R389.
22. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011;6:e22024.
23. Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013;119:1652-1659.
24. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006;8:R12.
25. Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer 2014;24:233-237.
26. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. V. 1.2008. Fort Washington (PA): NCCN, 2008 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site (20 May 2015, date last accessed).
27. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010;28:240-244.
28. Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol 2014;32:1093-1094.
29. Pavone ME, Mittal N, Smith K, Giordano SB. Amh values in reproductive aged women with and without the brca1 mutation. Fertil Steril 2014;102:e156.
30. Phillips KA, Butow PN, Stewart AE, Chang JH, Weideman PC, Price MA, McLachlan SA, Lindeman GJ, McKay MJ, Friedlander ML et al. Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Fam Cancer 2005;4:105-113.
31. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
32. Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Gorski B, Zielinska D, Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006;100:59-63.
33. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow S, Randolph JF Jr. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-3483.
34. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD. Antimullerian hormone as a predictor of natural fecundability in women aged 30- 42 years. Obstet Gynecol 2011;117:798-804.
35. Stolk L, Perry JR, Chasman DI, He C, Mangino M, Sulem P, Barbalic M, Broer L, Byrne EM, Ernst F et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet 2012;44:260-268.
36. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013;137:571-577.
37. Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab 2013;98:729-735.
38. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra121.
39. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007;22:1837-1840.
40. Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, Alexander C, Karlan BY. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril 2014;102:1723-1728.
41. Whitworth KW, Baird DD, Steiner AZ, Bornman RM, Travlos GS, Wilson RE, Longnecker MP. Anti-mullerian hormone and lifestyle, reproductive, and environmental factors among women in rural South Africa. Epidemiology 2015;26:429-435.